CClinicalTrials.gg
Sign In
Status unknownNCT02977650Updated Nov 30, 2016

EUS-FNA for Patients Taking Anticoagulants Without Heparin Bridge

An observational study in Endoscopic Ultrasonography-guided Fine Needle Aspiration, sponsored by Hokkaido Pancreatobiliary Endoscopic Intervention Study Group. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Hokkaido Pancreatobiliary Endoscopic Intervention Study Group · Observational

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
20 Years and older
Sex
All
01

Study summary

To evaluate the feasibility of EUS-FNA for patients taking anticoagulants without heparin bridge.

02

Conditions studied

  • Endoscopic Ultrasonography-guided Fine Needle Aspiration
03

In context

Lead sponsor

Hokkaido Pancreatobiliary Endoscopic Intervention Study Group is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients taking anticoagulants who underwent EUS-FNA

Inclusion criteria

  • Taking anticoagulants
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Platelets count less than 50000/μl
  • PT-INR more than 2.6
  • ASA more than 3
  • Severe bleeding tendency
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • ProcedureEndoscopic ultrasonography-guided fine needle aspiration

    Also known as: EUS-FNA

06

What researchers measure

Primary outcomes

  1. The rate of bleeding adverse events

    Time frame: Within 2 weeks

Secondary outcomes

  1. The rate of thromboembolic events

    Time frame: Within 2 weeks

  2. The rate of other adverse events

    Time frame: Within 2 weeks

07

Study locations

1 of 1 sites recruiting
  • Hokkaido University Hospital
    Sapporo, 0608638, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02977650
Lead sponsor
Hokkaido Pancreatobiliary Endoscopic Intervention Study Group
Responsible party
Kazumichi Kawakubo (M.D., Ph.D., Hokkaido Pancreatobiliary Endoscopic Intervention Study Group) — Principal investigator
First posted
Nov 30, 2016
Start date
Nov 2016
Primary completion
Nov 2016
Last update
Nov 30, 2016

Study contacts

Kazumichi Kawakubo, Ph.D.
Contact
kkawakubo-gi@umin.ac.jp
117161161

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Hokkaido Pancreatobiliary Endoscopic Intervention Study Group

Start the discussion